Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

The prevalence of measles antibody in human immunodeficiency virus-infected patients in northern California 5th International Conference on Travel Medicine Kemper, C. A., Gangar, M., ARIAS, G., Kane, C., Deresinski, S. C. UNIV CHICAGO PRESS. 1998: 1177–80

Abstract

The seroprevalence of measles (rubeola) antibody in 619 human immunodeficiency virus (HIV)-infected adults was determined by a standard ELISA. Risk factors for a lack of antibody and presumed susceptibility to measles were examined. Whereas overall, 9.8% of patients (60) were found to lack antibody, 17.8% of those born within the United States in 1957 or later were antibody-negative. Multivariate analysis showed that absence of measles antibody was significantly associated with younger age (born in 1957 or later) (odds ratio [OR], 8.15; 95% confidence interval [CI], 3.7-21.5; P < .0001) and birth within the United States (OR, 4.72; 95% CI, 1.7-19.7; P = .0045). Neither minority status, stage of HIV infection, CD4 cell count, nor a history of opportunistic infection bore any relationship to the presence of antibody. While progression of HIV disease does not affect measles serostatus, younger HIV-infected patients, especially those born in the United States in 1957 or later, are at the greatest risk for measles.

View details for Web of Science ID 000076248000039

View details for PubMedID 9806055